Neurobion Indications

Adjudication Rule

Abstract

For Members

Neurobion is a complex vitamin supplement containing; Vitamin B1, Vitamin B6, and Vitamin B12. It is indicated, where deficiency of the relevant vitamins exists. Due to its important effect on nerve regeneration it is commonly prescribed for various neurological deficits. Neurobion is covered for all health insurance plans administered by Daman (subject to policy terms and conditions), if medically indicated.

For Medical Professionals

Neurobion is covered for all health insurance plans administered by Daman (subject to policy terms and conditions), if medically indicated.

Indications of Neurobion are:

- Mono and polyneuropathies of any origin such as diabetic, alcoholic or toxic neuropathies,
- Neuritis or Neuralgia (especially cervical syndrome, shoulder-arms syndrome),
- Sciatica, and
- Herpes zoster
- Deficiency of relevant vitamins

Due to its important effect on nerve regeneration it is commonly prescribed for various neurological deficits. Neurobion is covered for all health insurance plans administered by Daman (subject to policy terms and conditions), if medically indicated.

Disclaimer

By accessing these Daman Adjudication Rules (the “AR”), you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this AR is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter “Daman”). The AR is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman AR. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This AR does not grant any rights or impose obligations on Daman. The AR and all of the information it contains are provided “as is” without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this AR, including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website. This AR is subject to the laws, decrees, circulars and regulations related to the AR as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties. This AR is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman’s express written consent. This AR incorporates the Current Procedural Terminology and Current Dental Terminology (CPT®) and CDT® codes, which is a registered trademark of the American Medical Association (“AMA”), and the American Dental Association (“ADA”) respectively; and the CPT and CDT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the AR at any time by providing one month prior notice.

Approved by:
Daman

Responsible:
Medical Strategy & Development Department

Related Adjudication Rules:
None

Table of content

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Scope</th>
<th>Adjudication Policy</th>
<th>Adjudication examples</th>
<th>Denial codes</th>
<th>Appendices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 1</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 2</td>
<td>Page 2</td>
</tr>
</tbody>
</table>
**Neurobion Indications**

**Scope**

This guideline aims to specify the coverage details of Neurobion for all health insurance plans administered by Daman.

Neurobion is a combination of neurotropic vitamins B1, B6, & B12, marketed by Merck. These vitamins in their role as co-enzymes are indispensable factors in the metabolism of the nervous system. Neurobion normalizes the nerve cell metabolism. Neurobion supports the regeneration of nerve fiber and myelin sheath by activation of the metabolism and the natural repair mechanism.

**Adjudication Policy**

**Eligibility / Coverage Criteria**

Neurobion is covered for all health insurance plans administered by Daman (subject to policy terms and conditions), if medically indicated. Indications for Neurobion are:

- Mono and polyneuropathies of any origin such as diabetic, alcoholic or toxic neuropathies,
- Neuritis or Neuralgia (especially cervical syndrome, shoulder-arms syndrome),
- Sciatica, and
- Herpes zoster
- Deficiency of relevant vitamins

**Requirements for Coverage**

ICD and CPT codes must be coded to the highest level of specificity.

**Non-Coverage**

Neurobion, if medically indicated is covered for all health insurance plans administered by Daman (subject to policy terms and conditions).

**Payment and Coding Rules**

Please apply HAAD payment rules and regulation and relevant coding manuals for ICD, CPT, etc.

**Adjudication Examples**

**Example 1**

**Question:** A 38 year old Regional card holder was diagnosed with ‘Type II Diabetes Mellitus With Neurological Manifestations’ and ‘Polyneuropathy in Diabetes’ and advised to take Neurobion by his treating physician. Will the drug be covered for this patient?

**Answer:** Yes, The claim will be paid.

**Example 2**

**Question:** A 47 year old Basic card holder was diagnosed with ‘Alcoholic Polyneuropathy’ and advised to take Neurobion by his treating physician. Will the drug be covered for this patient?

**Answer:** No, The claim will be rejected as any treatment related to alcoholism is a general exclusion in this plan.

**Denial codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNEC-004</td>
<td>Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities</td>
</tr>
<tr>
<td>NCOV-001</td>
<td>Diagnosis(es) is (are) not covered</td>
</tr>
<tr>
<td>MNEC-003</td>
<td>Service is not clinically indicated based on good clinical practice</td>
</tr>
<tr>
<td>MNEC-005</td>
<td>Service/supply maybe appropriate, but too frequent</td>
</tr>
</tbody>
</table>

**Appendices**

A. **References**

1. Martindale drug information
2. Neurobion drug leaflet

B. **Revision History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01-07-13</td>
<td>V 2.0: New template</td>
</tr>
</tbody>
</table>
| 15-07-14 | 1. V 4.0  
2. Disclaimer updated as per system requirements  
3. Restored original effective date                  |